<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114299">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889667</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-009</org_study_id>
    <secondary_id>ORMD-0801</secondary_id>
    <nct_id>NCT01889667</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Oral Bedtime Doses of ORMD-0801(Insulin Capsules) in Adult Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Diet and Exercise or Diet, Exercise and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and pharmacodynamics of an  oral formulation
      of insulin in subjects with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, Phase II(a), randomized, double-blind, placebo-controlled, parallel
      group, inpatient study preceded by a 5-day single-blind outpatient placebo run-in period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability as assessed by numbers of adverse events</measure>
    <time_frame>Eight (8) days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events collected during study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of ORMD-0801 on weighted mean night time glucose levels of continuous glucose monitor (CGM) data at the end of the seven (7)- day treatment period as determined by comparison to the effect in the group receiving placebo</measure>
    <time_frame>Seven (7) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of ORMD-0801 on area under the curve (AUC), Cmax, Tmax, and T½</measure>
    <time_frame>Nineteen (19) time points on each of two (2) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes from baseline in fasting blood (finger stick) glucose</measure>
    <time_frame>Screening + seventeen (17) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ORMD-0801 on Morning fasting blood glucose by finger stick compared to pre-treatment placebo run-in period</measure>
    <time_frame>average of last five (5) of the seven (7) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ORMD-0801 on morning fasting serum insulin compared to placebo</measure>
    <time_frame>Screening + four (4) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ORMD-0801 on morning fasting C-peptide compared to placebo</measure>
    <time_frame>Screening + four (4) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ORMD-0801 on morning fasting blood glucose compared to placebo</measure>
    <time_frame>Screening + four (4) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ORMD-0801 on morning fasting blood glucose by finger stick compared to group receiving placebo</measure>
    <time_frame>average of last of the seven (7) days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose # 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Insulin Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose # 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Insulin Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oil Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 Dose # 1</intervention_name>
    <description>Oral Insulin Formulation</description>
    <arm_group_label>ORMD-0801 Dose # 1</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 Dose # 2</intervention_name>
    <description>Oral Insulin Formulation</description>
    <arm_group_label>ORMD-0801 Dose # 2</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oil Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, age 20 to 70 years, inclusive with type 2 diabetes;

          -  At time of randomization, patients will be treated for their diabetes by diet and
             exercise, or by diet, exercise and metformin (&gt;1000 mg/day; any type and regimen).
             Patients will have been on a stable regimen of metformin (defined as the same
             metformin dose and type) for at least 6 weeks prior to entering the placebo run-in
             period. Other anti-diabetic agents will not have been in use for the 6 weeks prior to
             entering the placebo run-in period;

          -  Body Mass Index (BMI) between 25 and 40 kg/m2, inclusive;

          -  Hemoglobin A1c (HbA1c) between 6.5 -10.5%, inclusive, prior to randomization)

          -  Fasting plasma glucose greater than or equal to 126 mg/dL (8.3 mmo1/L) prior  to
             randomization;

          -  No tobacco or nicotine use within 10 weeks prior to screening;

          -  Females of child-bearing potential must have a negative serum pregnancy test result
             at screening and a negative urine pregnancy test at Visit 3. Females of
             non-childbearing potential are defined as postmenopausal who:

               1. had more than 24 months since last menstrual cycle with menopausal levels of
                  follicle stimulating hormone(FSH);

               2. are greater than 55 years old; or

               3. are surgically menopausal.

        Exclusion Criteria:

          -  Presence of any clinically significant endocrine disease according to the
             Investigator;

          -  Clinical diagnosis of Type 1 diabetes;

          -  Fasting plasma glucose &gt;260 mg/dL at the end of washout/stabilization/run-in periods;

          -  Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤50 mg/dL in the
             absence of symptoms of hypoglycemia;

          -  Presence of any clinically significant condition that might interfere with the
             evaluation of study medication;

          -  Presence or history of cancer within the past five years with the exception of
             adequately-treated localized basal cell skin cancer or in situ uterine cervical
             cancer;

          -  Laboratory abnormalities at screening including

               1. C-peptide &lt; 1.0 ng/mL;

               2. Positive pregnancy test in females of childbearing potential (at screening and
                  start of run-in period);

               3. Abnormal serum thyrotropin (TSH) levels &gt; 1.5 times the upper limit of normal;

               4. Positive test for hepatitis B surface antigen and/or hepatitis C antibody;

               5. Positive test for HIV;

               6. Any relevant abnormality interfering with the efficacy or the safety assessments
                  during study drug administration;

          -  Use of the following medications

               1. History of use of insulin for no more than 1 week in the last 6 months and none
                  in the last 6 weeks prior to randomization;

               2. History of use of aprotinin at any time prior to the screening visit;

               3. Administration of anti-diabetic drugs other than metformin within 6 weeks prior
                  to run-in period;

               4. Administration of thiazolidinedione treatment within 3 months prior to
                  randomization;

               5. Administration of thyroid preparations or thyroxine (except in patients on
                  stable replacement therapy) within 6 weeks prior to screening visit;

               6. Administration of systemic long-acting corticosteroids within two months or
                  prolonged use of other systemic corticosteroids or inhaled corticosteroids
                  within 30 days prior to screening visit;

               7. Use of medications known to modify glucose metabolism or to decrease the ability
                  to recover from hypoglycemia such as oral, parenteral, and inhaled steroids,
                  beta blockers (with the exception of beta blocker ophthalmic solutions for
                  glaucoma or ocular hypertension), and immunosuppressive or immunomodulating
                  agents.

          -  History of severe or multiple allergies;

          -  History of tobacco or nicotine use within 10 weeks prior to screening

          -  Patient is on a weight loss program and is not in the maintenance phase, or patient
             that started weight loss medication within 8 weeks prior to screening;

          -  Pregnancy or breast-feeding;

          -  Patient has a screening visit systolic blood pressure of ≥165 mm Hg or diastolic
             blood pressure of ≥100 mm Hg. Patients will be allowed to take a BP rescue medication
             as long as it does not affect glucose metabolism (e.g., diuretics) or sensation of
             hypoglycemia (e.g., beta-blockers);

          -  Patient is, at the time of signing informed consent, a user of recreational or
             illicit drugs or has had a recent history (within the last year) of drug or alcohol
             abuse or dependence;

          -  Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST),
             alkaline phosphatase) greater than 2 times the upper limit of normal at screening;

          -  Very high triglyceride level (&gt;600 mg/dL) at screening;

          -  Any clinically significant ECG abnormality at screening or cardiovascular disease.
             Clinically significant cardiovascular disease will include

               1. history of stroke, transient ischemic attack, or myocardial infarction within 6
                  months prior to screening;

               2. history of or currently have New York Heart Associate Class II-IV heart failure
                  prior to screening; or

               3. uncontrolled hypertension defined as blood pressure ≥180 mmHg (systolic) or ≥110
                  mmHG (diastolic) at screening or at Visit 2;

          -  One or more contraindications to metformin;

          -  History of gastrointestinal disorders with the potential to interfere with drug
             absorption;

        At the Principal Investigator's discretion, any condition or other factor that is deemed
        unsuitable for patient enrollment into the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Neutel, M. D.</last_name>
    <role>Study Director</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Kidron, Ph.D.</last_name>
    <email>kidron@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel M Neutel, M. D.</last_name>
      <phone>714-550-9990</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>June 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Insulin</keyword>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
